Business Context and Reporting Period
Company: OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 18, 2008
Context: The Company is amending and restating its 401(k) Profit Sharing Plan and Trust to utilize a plan document provided by Fidelity Investments. This change involves removing Company securities as an investment option and altering available investment choices.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on administrative changes to employee benefit plans.
Material Changes
- Plan Restructuring: The 401(k) plan is being restated with Fidelity Investments as the Trustee.
- Investment Options: Company securities will no longer be offered as an investment option within the plan.
- Trading Suspension: A temporary suspension of trading (blackout period) is being implemented for directors and executive officers.
Guidance, Outlook, and Risks
Blackout Period Details:
- Commencement Date: January 11, 2009
- Expected End Date: March 8, 2009
- Restrictions: During this period, participants cannot direct investments, obtain loans, or receive distributions. Directors and executive officers are prohibited from purchasing, selling, or transferring Company common stock or exercising stock options.
Investor Verification Checklist
- Verify the exact dates of the blackout period (January 11, 2009 to March 8, 2009) to ensure compliance with trading restrictions.
- Confirm the removal of Company stock as an investment option in the 401(k) plan.
- Review the attached Exhibit 99.1 for the full text of the notice sent to directors and executive officers.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.